SCHEMBL2272939

SCHEMBL2272939

O=C(Nc1cc(-c2cccc(Cl)c2)ccc1C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 5/20 0.71
PPARG P37231 2/20 0.62
PPARD Q03181 2/20 0.62
NR1H4 Q96RI1 2/20 0.62
PPARA Q07869 1/20 0.62
KCNK2 O95069 2/20 0.58
KCNK10 P57789 2/20 0.58
SERPINE1 P05121 2/20 0.56
GRIK1 P39086 3/20 0.56
HDAC2 Q92769 1/20 0.54
SUCNR1 Q9BXA5 1/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
PKM P14618 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
DHODH Q02127 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267918 0.89 ACLY (0.74) ACLYPPARGPPARDNR1H4PPARA
SCHEMBL2272927 0.88 ACLY (0.64) ACLYKCNK2KCNK10SERPINE1GRIK1
SCHEMBL2276482 0.88 ACLY (0.74) ACLYSERPINE1GRIK1HDAC2SUCNR1
SCHEMBL2277993 0.87 ACLY (0.65) ACLYKCNK2KCNK10SERPINE1GRIK1
SCHEMBL2274927 0.83 ACLY (0.63) ACLYPPARGPPARDNR1H4PPARA
SCHEMBL21930987 0.83 ACLY (1.00) ACLYSERPINE1HDAC2SUCNR1
SCHEMBL2269733 0.82 ACLY (0.59) ACLYKCNK2KCNK10SERPINE1GRIK1
SCHEMBL2274563 0.82 ACLY (0.81) ACLYSERPINE1GRIK1SUCNR1KMT2A
SCHEMBL2274998 0.81 ACLY (0.80) ACLYKCNK2KCNK10SERPINE1GRIK1
SCHEMBL2276184 0.81 ACLY (0.73) ACLYHDAC2SUCNR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885PPARG 2066/4885PPARD 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.